News
GSK files Blenrep in EU, seeking return to market

GSK files Blenrep in EU, seeking return to market

Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its bloc

News
Cardurion heads crop of sizeable bio financings

Cardurion heads crop of sizeable bio financings

While the pace of biotech private rounds seems to have slowed a little of late, this week saw four big financings for Cardurion Pharma, Scorpion Therapeutics, CatalYm, and NGM Bio.

News
Cardurion heads crop of sizeable bio financings

Cardurion heads crop of sizeable bio financings

While the pace of biotech private rounds seems to have slowed a little of late, this week saw four big financings for Cardurion Pharma, Scorpion Therapeutics, CatalYm, and NGM Bio.

News

News
GSK files Blenrep in EU, seeking return to market

GSK files Blenrep in EU, seeking return to market

Less than two years after pulling multiple myeloma therapy Blenrep off most markets around the world, GSK has filed for approval of the drug in the EU once again, hoping to restore its bloc

Views & Analysis

Oncology
ASCO 2024 - Chris Haqq interview with Jonah Comstock

ASCO 2024 - Chris Haqq

ASCO isn’t just a show for top 10 pharmas and Phase 3 readouts; it’s also a conference where smaller biopharmas share encouraging early-stage results, especially those that point to a new p

Deep Dive

Oncology
hexagon graphic

Heard on the pipeline: ASCO 2024

pharmaphorum's Jonah Comstock polls ASCO 2024 attendees on their best advice for oncology newcomers, capturing insights on scientific prowess, collaborative spirit, and navigating cutting-edge clinical trials.

Newsletters and Deep Dive
digital magazine

Webinars

/themes/custom/pharmaphorum_theme/library/img/article-label-image/ondemand.png
Oncology
Print
Sponsored

Clinical decision-making insights for haem/oncs

Despite the effects of countries’ lockdown policies, a plethora of clinical trial readouts continue to emerge providing several decision-making challenges for healthcare professionals.

Podcasts

Video

Oncology
ASCO 2024 - Steve Devine interview with Jonah Comstock

ASCO 2024 - Steve Devine

While advances in cell and gene therapies chip away at the need for bone marrow transplants, the transplantation field remains very much alive and in the midst of innovations of its own.

Oncology
ASCO 2024 - Chris Haqq interview with Jonah Comstock

ASCO 2024 - Chris Haqq

ASCO isn’t just a show for top 10 pharmas and Phase 3 readouts; it’s also a conference where smaller biopharmas share encouraging early-stage results, especially those that point to a new p

Oncology
Michael Petroutsas at ASCO 2024

ASCO 2024 - Michael Petroutsas

Just two months into his new position as US president and head of commercial for Astellas, Michael Petroutsas joined pharmaphorum editor-in-chief Jonah Comstock for a conversation on the si

White Papers

Debates & Insight

Partner Content

Oncology
8th Tumor Models San Francisco Summit 2024
Partner Content

8th Tumor Models San Francisco Summit 2024

Following Merck announcing their goal to phase out animal use in their work, Astellas and MIMETAS expanding their partnership in immunotherapeutic development, and the domino effects across the fie